AVITA Medical Inc (RCEL) — Titan Protect Analysis

RCEL

AVITA Medical Inc

Healthcare · ·

$4.18

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$127M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.06

Based on estimated future earnings — lower means cheaper

Rev Growth

+4.0%

Year-over-year revenue change

Profit Margin

-62.7%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+43% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About AVITA Medical Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to

https://avitamedical.com

Country: United States Employees: 226 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.055

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0371

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.423

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-32.5%

Historical annualised return based on price data

Max Drawdown

-76.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.90

Significantly more volatile than the market

52W High

$7.12

41% below the year high

52W Low

$3.22

30% above the year low

Avg Volume

229,566

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.56

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

81.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-45.7%

Profit from core operations before interest and tax

Free Cash Flow

$-18,312,124

Negative — the business is spending more than it generates

Revenue (TTM)

$72M

Total revenue over the last 12 months

Net Income

$-45,339,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.12

Target Median

$6.00

Target Low

$5.44

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go